Vaxcyte, Inc. (PCVX) Financials
PCVX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 3.1 billion | 380.2 million |
| March 31, 2026 | 3.3 billion | 352.3 million |
| Dec. 31, 2025 | 3.0 billion | 360.5 million |
| Sept. 30, 2025 | 3.2 billion | 278.7 million |
PCVX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -532.5 million | 79.2 million |
| March 31, 2026 | -295.4 million | 38.0 million |
| Dec. 31, 2025 | -219.3 million | 36.0 million |
| Sept. 30, 2025 | -155.4 million | 35.3 million |
PCVX Net Income
No data available :(
PCVX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 1.5 billion | - | 115.4 million |
| March 31, 2026 | 1.7 billion | - | 110.2 million |
| Dec. 31, 2025 | 1.6 billion | 111.4 million | 111.4 million |
| Sept. 30, 2025 | 1.7 billion | - | 78.7 million |
PCVX Shares Outstanding
PCVX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 19.4 million | 267.9 million | 34.9 million | - |
| March 31, 2026 | 14.8 million | 312.8 million | 33.1 million | - |
| Dec. 31, 2025 | 5.6 million | 242.1 million | 32.2 million | - |
| Sept. 30, 2025 | 12.0 million | 209.9 million | 32.4 million | - |
PCVX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | 5.9 million |
| Dec. 31, 2025 | - | -5.0 million |
| Sept. 30, 2025 | - | - |
PCVX Revenue by Segment
Graph available only for paid members. Upgrade to see it.
PCVX
Price: $67.55
52 week price:
Earnings Per Share: -7.75 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 346400
Market Capitalization: 8.2 billion